BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
Biogen gains after securing Greater China rights to felzartamab, giving it worldwide control as phase III studies advance in immune diseases.
Zacks·13h ago
More News
Align Technology's Q1 Earnings on Deck: Here's What to Expect
ALGN's Q1 report looms with revenues seen rising 4.3% and EPS up 6.1%, as Invisalign demand and iTero adoption drive growth trends.
Zacks·14h ago
HSBC Predicts Biogen's Q1 Earnings (NASDAQ:BIIB)
Biogen Inc. (NASDAQ:BIIB - Free Report) - Investment analysts at HSBC issued their Q1 2026 earnings per share estimates for shares of Biogen in a research note issued to investors on Friday, April...
MarketBeat·19h ago
Mirae Asset Global Investments Co. Ltd. Decreases Position in Biogen Inc. $BIIB
Mirae Asset Global Investments Co. Ltd. cut its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 47.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned...
MarketBeat·19h ago
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS...
Business Wire·1d ago
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.
Zacks·1d ago
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.
Zacks·2d ago
Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Microsoft, Amazon, Ulta Beauty, Okta, Biogen, Meta & more
Here are the biggest calls on Wall Street on Monday...
CNBC: Top News·2d ago
Zurcher Kantonalbank Zurich Cantonalbank Buys 104,038 Shares of Biogen Inc. $BIIB
Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 29.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 452,442 shares of the biotechnology company's stock after pur...
MarketBeat·2d ago
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region PR Newswire CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 With this transaction, Biogen now owns...